Novo Nordisk's Wegovy Shows Greater Weight Loss in Women

Novo Nordisk's obesity treatment Wegovy (semaglutide) showed greater weight loss in women with heart failure than in men, based on a study presented at the American Diabetes Association's 2024 Scientific Sessions. While both sexes experienced significant weight loss with semaglutide, women saw a more pronounced reduction. The drug improved HFpEF symptoms and exercise capacity similarly in both men and women. The trials did not specifically evaluate the drug's effects based on biological sex, and further research is needed to understand the differences in weight loss outcomes. Novo Nordisk's Wegovy has the potential to benefit heart failure patients, with fewer serious adverse events reported among those receiving the drug.